Phase 2 Type 2 Diabetes Trial, Recruiting (NCT06031428)

Phase 2 Type 2 Diabetes Trial, Recruiting NCT06031428 Sponsor: Medical College of Wisconsin Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06031428 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older
People who identify as Black or African American
People who identify as male
People who have previously been held in a state or federal prison or a county jail
People who have been medically diagnosed with type 2 diabetes and have a blood sugar control reading (called HbA1c) of 8% or higher at the initial screening appointment
People who are able to communicate in English

Who may not be able to join:

People who show signs of significant memory or thinking problems during the screening interview
People who are currently taking part in another clinical trial for diabetes
People who are currently experiencing active psychosis or an acute mental health crisis
People whose life expectancy is less than 12 months
People who are currently awaiting court arraignment, trial, or sentencing in the criminal legal system
People who are currently under active supervision by the criminal legal system, such as being on house arrest or monitored by an electronic device

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Laura Hawks, MD, Medical College of Wisconsin

Phone: 414-955-8020

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06031428

Sponsor: Medical College of Wisconsin

Phase: Phase 2

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 414-955-8020

More information: https://clinicaltrials.gov/study/NCT06031428

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older
People who identify as Black or African American
People who identify as male
People who have previously been held in a state or federal prison or a county jail
People who have been medically diagnosed with type 2 diabetes and have a blood sugar control reading (called HbA1c) of 8% or higher at the initial screening appointment
People who are able to communicate in English

Who may not be able to join:

People who show signs of significant memory or thinking problems during the screening interview
People who are currently taking part in another clinical trial for diabetes
People who are currently experiencing active psychosis or an acute mental health crisis
People whose life expectancy is less than 12 months
People who are currently awaiting court arraignment, trial, or sentencing in the criminal legal system
People who are currently under active supervision by the criminal legal system, such as being on house arrest or monitored by an electronic device

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Medical College of Wisconsin

Registry

ClinicalTrials.gov

Start date

20 February 2024

Est. completion

1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hemoglobin A1C

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov